Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Hilpert

Showing results (11-20 of 107) with videos related to

Pageof 11
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 28, 2017
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancerFlorence Joly, Felix Hilpert, Aikou Okamoto, et al.
Expert Review of Anticancer Therapy|July 11, 2009
Role of cytoreductive surgery in recurrent ovarian cancerPhilipp Harter, Felix Hilpert, Sven Mahner, et al.
Expert Review of Anticancer Therapy|December 18, 2009
Systemic therapy in recurrent ovarian cancer: current treatment options and new drugsPhilipp Harter, Felix Hilpert, Sven Mahner, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 4, 2009
Prognostic factors for complete debulking in first- and second-line ovarian cancerPhilipp Harter, Felix Hilpert, Sven Mahner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxelElfriede R Greimel, Vesna Bjelic-Radisic, Jacobus Pfisterer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 26, 2012
Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancerAndreas du Bois, Christian Marth, Jacobus Pfisterer, et al.
Archives of Gynecology and Obstetrics|May 26, 2011
Diagnosis and management of an unilateral giant fibroadenoma of the breast in pregnancyThorsten Heilmann, Ivo Leuschner, Felix Hilpert, et al.
Investigational New Drugs|September 6, 2013
Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)Philipp Harter, Jalid Sehouli, Rainer Kimmig, et al.
Auris, Nasus, Larynx|May 4, 2004
A dendritic cell based hybrid cell vaccine generated by electrofusion for immunotherapy strategies in HNSCCJan Bernd Weise, Steffen Maune, Tibor Görögh, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 10, 2010
Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trialsElfriede R Greimel, Vesna Bjelic-Radisic, Jacobus Pfisterer, et al.
Pageof 11

Showing results (11-20 of 107) with videos related to

Sort By:
Pageof 11
European Journal of Cancer (Oxford, England : 1990)|April 28, 2017
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancerFlorence Joly, Felix Hilpert, Aikou Okamoto, et al.
Expert Review of Anticancer Therapy|July 11, 2009
Role of cytoreductive surgery in recurrent ovarian cancerPhilipp Harter, Felix Hilpert, Sven Mahner, et al.
Expert Review of Anticancer Therapy|December 18, 2009
Systemic therapy in recurrent ovarian cancer: current treatment options and new drugsPhilipp Harter, Felix Hilpert, Sven Mahner, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 4, 2009
Prognostic factors for complete debulking in first- and second-line ovarian cancerPhilipp Harter, Felix Hilpert, Sven Mahner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxelElfriede R Greimel, Vesna Bjelic-Radisic, Jacobus Pfisterer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 26, 2012
Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancerAndreas du Bois, Christian Marth, Jacobus Pfisterer, et al.
Archives of Gynecology and Obstetrics|May 26, 2011
Diagnosis and management of an unilateral giant fibroadenoma of the breast in pregnancyThorsten Heilmann, Ivo Leuschner, Felix Hilpert, et al.
Investigational New Drugs|September 6, 2013
Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)Philipp Harter, Jalid Sehouli, Rainer Kimmig, et al.
Auris, Nasus, Larynx|May 4, 2004
A dendritic cell based hybrid cell vaccine generated by electrofusion for immunotherapy strategies in HNSCCJan Bernd Weise, Steffen Maune, Tibor Görögh, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 10, 2010
Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trialsElfriede R Greimel, Vesna Bjelic-Radisic, Jacobus Pfisterer, et al.
Pageof 11